I am a board-certified diagnostic radiologist with special expertise in the imaging of the nervous system (neuroradiology). I specialize in anatomic and functional CT and MRI of the brain, neck, and spine.
As a physician-scientist, I also pursue laboratory research in an effort to refine imaging methods and develop new approaches that can be taken to the clinic and used to gather more information about tumors, and also to deliver novel therapies. Specifically, as a member of the Nano Center, I am collaborating with other investigators at Memorial Sloan Kettering and the Department of Material Sciences and Engineering at Cornell University in Ithaca to design and develop very tiny substances called nanoparticles that can be used to detect and treat tumors and associated metastatic disease (cancer spread).
Because these particles attach to specific cells, they could serve as tracers, tagged with both a fluorescent dye and radiolabelled and visualized with optical and PET imaging to detect tumor cells and metastases in the body more effectively than the tracers we use today. They may even potentially be used by surgeons right in the operating room to assess the extent of tumor spread. Sentinel lymph node mapping (a staging procedure using these tracers to see if the first node to which cancer cells would spread actually contains cancer cells) is one such study that is under way in animal models, in collaboration with the Head and Neck Service in the Department of Surgery. In addition, we are in the process of attaching therapeutic drugs to these nanoparticles, so they may also have a place in cancer therapy. These studies began in the laboratory and are moving into clinical trials in collaboration with the Department of Surgery.
With my colleagues in the Brain Tumor Center, I am studying the use of a piece of a protein called a peptide which is attached to a chemotherapy drug for the treatment of brain tumors. This complex could possibly be more successful in passing through the blood-brain barrier and get to tumor cells more effectively than conventional drugs. I am also evaluating new ways to combine MRI findings with data from PET scanning to gain more knowledge about the molecular biology of brain tumors.
In all of my research, my goal is to develop novel approaches that increase our ability to target tumor cells to improve the diagnosis, staging, and treatment of cancers, and to ultimately improve survival and prognosis for patients.
- Clinical Expertise: Neuroradiology
- Languages Spoken: English
- Education: MD, George Washington University School of Medicine; PhD, Massachusetts Institute of Technology
- Residencies: Bowman Gray School of Medicine/Baptist Medical Center
- Fellowships: Bowman Gray School of Medicine/Baptist Medical Center
- Board Certifications: Diagnostic Radiology
Bradbury MS, Hambardzumyan D, Zanzonico P, Schwartz J, Cai S, Burnazi E, Larson SM, and Holland EC. PET imaging of tumor proliferation in genetically engineered mouse models of human glioma using 18F-FLT (submitted, J Nucl Med).
Peck K, Bradbury MS, Petrovich N, Hou B, Brennan C, Tabar V, and Holodny A. Preoperative susceptibility artifacts in brain tumor patients: can fMRI effectively assess language laterality? (submitted, Journal of Neurology, Neurosurgery, and Psychiatry).
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more